Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats
[15] [39] [40] In August 2025, the Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of noncirrhotic metabolic-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults
Some metabolites, such as SCFAs, are produced by the GM directly from diets, while others, such as secondary BAs, are generated by the host and then modified by the GM
Structural changes such as cardiomyopathy, cardiac hypertrophy, interstitial cardiac fibrosis, endothelial dysfunction, and contractile protein failure can result from elevated oxidative stress in cardiac tissue (Emran et al